




Access to medicines – high and unsustainable price levels

Secretary General Dr Bjørn-Inge Larsen
Norwegian Ministry of Health and Care Services

Brussels November 14, 2019




Norwegian Minister of Health, Mr Bent Høie


"Unethically high prices on some new medicines"




About Norway



Norwegian Health System – key principles



Decisions on access - The main components of the system



Norwegian health system – the cost of sustainability






«Cost is a
relevant ethical
argument»

Prof. Dr. Theol. Inge Lønning
1938 – 2013


Photo: Dagbladet.no



Spending on health care per capita (2018)




Rate of availability (%)



Rate of availability


ACCESS DECISIONS
2018

■ No ■ Yes ■ Other




"NO ACCESS" DECISIONS 2018

■ Oncology ■ MS ■ Other ■ Psoriasis



Oncologics uptake by country



Oncologics includes: ABIRATERONE ACETATE, ENZALUTAMIDE, PERTUZUMAB, TRASTUZUMAB EMTANSINE, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB, RAMUCIRUMAB, IBRUTINIB, PALBOCICLIB
Source: IMS Health MIDAS Mat Q4 2015 (EFPIA)




Secret prices of medicines



shutterstock.com • 740131342



Cost per QALY vs. Public Health Services



The social contract



What is next?

- European Commission
- National agendas
- Collaboration initiatives: WHO, OECD
- Dialogue with industry
- Dialogue with patient organizations





Helse- og
omsorgsdepartementet